COMPOSITION FOR TREATMENT, ALLEVIATION OR PROPHYLAXIS OF ACNE
A composition comprises one or more of bacterial strains wherein the one or more of bacterial strains exhibit a stronger inhibition of pathogenic C. acnes strains compared to non-pathogenic C. acnes strains.
1 . A composition comprising one or more of bacterial strains wherein the one or more of bacterial strains exhibit a stronger inhibition of pathogenic Cutibacterium acnes strains compared to non-pathogenic Cutibacterium acnes strains.
2 . The composition according to claim 1 , wherein the inhibition is a growth inhibition, co-aggregation inhibition, biofilm inhibition, or a combination hereof, of the C. acnes strains.
3 . The composition according to claim 1 , wherein the composition comprising one or more of bacterial strains capable of co-aggregating stronger to one or more pathogenic C. acnes strains relative to the capability of the one or more bacterial strains to co-aggregation to one or more non-pathogenic C. acnes strains.
4 . The composition according to claim 1 , wherein the inhibition of pathogenic C. acnes strains is 10% stronger or more relative to the inhibition of the non-pathogenic C. acnes strains.
5 . The composition according to claim 1 , wherein the one or more pathogenic C. acnes strains is selected from a Cutibacterium acnes ribotype RT4; ribotype RT5; and ribotype RT8.
6 . The composition according to claim 1 , wherein the one or more bacterial strains is one or more lactic acid bacterial strains, preferably, the one or more lactic acid bacterial strains is a Lactobacillus strain; a Leuconostoc strain; and/or a Weissella strain, preferably, the bacterial strains is a Lactobacillus strain.
7 . The composition according to claim 6 , wherein the Lactobacillus strains is selected from Lactobacillus plantarum , preferably, the Lactobacillus plantarum is selected from Lactobacillus plantarum LB356R, deposited under DSM 33094 or from Lactobacillus plantarum LB244R, deposited under DSM 32996; or a combination hereof the Leuconostoc strains is selected from Leuconostoc mesenteriodes , preferably, the Leuconostoc mesenteriodes is selected from Leuconostoc mesenteriodes LB349A, deposited under DSM 33093; and/or the Weissella strains is selected from Weissella viridescens , preferably, the Weissella viridescens is selected from Weissella viridescens LB10G, deposited under DSM 32906.
8 . The composition according to claim 1 , wherein the co-aggregation forms aggregates within 1 hour having an aggregate particle size above 0.1 mm.
9 . The composition according to claim 1 , wherein the composition is a topical composition, an oral composition, or a rectal composition.
10 . The composition according to claim 1 , wherein the one or more bacterial strains is provided as one or more viable strains.
11 . The composition according to claim 1 , wherein the concentration of the one or more bacterial strains is in the range of 10 3 to 10 14 colony forming units (CFU).
12 . The composition according to claim 1 , wherein the pH of the composition is pH 6.5 or below.
13 . A pharmaceutical composition comprising the composition according to claim 1 , for use as a medicament.
14 . A method of treating; alleviating, suppressing; prophylaxis; and/or
preventing growth of a pathogenic micro-organism in a subject in need thereof comprising administering a therapeutically effective amount of the composition of claim 1 to the subject.
15 . A method of treating; alleviating, suppressing; prophylaxis; and/or preventing of acne vulgaris in a subject in need thereof comprising administering a therapeutically effective amount of the composition of claim 1 to the subject.